Metraipolis › archive › dc_ec920d97bdd4

Multi-omics biomarkers for predicting resistance, hyperprogression, and immune-related toxicity during PD-1/PD-L1 therapy in lung cancer: a literature review — Europe PMC PMID:42183274

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42183274
DOI
10.3389/fimmu.2026.1780459
License (as archived)
solo-consultazione
Archived
2026-11-02T14:38:52.255Z
SHA-256 of the archived text
6e271873e8bed2af29423500972f9249209bdd9552607711cdba26efa59a71c9
Stable URL of this page
https://metraipolis.com/documento/dc_ec920d97bdd4

How to cite

Multi-omics biomarkers for predicting resistance, hyperprogression, and immune-related toxicity during PD-1/PD-L1 therapy in lung cancer: a literature review — Europe PMC PMID:42183274 — Europe PMC (en), https://europepmc.org/article/MED/42183274 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ec920d97bdd4 (Metraipolis archive dc_ec920d97bdd4, sha256 6e271873e8bed2af29423500972f9249209bdd9552607711cdba26efa59a71c9)
BibTeX
@misc{dcec920d97bdd4,
  title = {Multi-omics biomarkers for predicting resistance, hyperprogression, and immune-related toxicity during PD-1/PD-L1 therapy in lung cancer: a literature review — Europe PMC PMID:42183274},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42183274},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ec920d97bdd4; sha256 6e271873e8bed2af29423500972f9249209bdd9552607711cdba26efa59a71c9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42183274. Agents can read the archived copy with the MCP tool read_document.